The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.

[1]  S. Roy,et al.  Surface‐functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Y. Takakura,et al.  Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy. , 2009, Advanced drug delivery reviews.

[3]  B. Stillman,et al.  Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug , 2009, Nature Biotechnology.

[4]  B. Teicher.  Acute and chronic in vivo therapeutic resistance. , 2009, Biochemical pharmacology.

[5]  J. Panyam,et al.  Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[6]  A. Hilgeroth,et al.  Recent advances in the development of P-gp inhibitors. , 2009, Anti-cancer agents in medicinal chemistry.

[7]  Russell J Mumper,et al.  Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. , 2009, Cancer research.

[8]  G. Szakács,et al.  Relevance of multidrug resistance in the age of targeted therapy. , 2009, Current opinion in drug discovery & development.

[9]  M. Edelman.  Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer. , 2009, Clinical lung cancer.

[10]  Mansoor M. Amiji,et al.  Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells , 2009, Cancer Chemotherapy and Pharmacology.

[11]  M. Dean.  ABC Transporters, Drug Resistance, and Cancer Stem Cells , 2009, Journal of Mammary Gland Biology and Neoplasia.

[12]  Jayanth Panyam,et al.  Polymeric nanoparticles for siRNA delivery and gene silencing. , 2009, International journal of pharmaceutics.

[13]  Jayanth Panyam,et al.  Single-step surface functionalization of polymeric nanoparticles for targeted drug delivery. , 2009, Biomaterials.

[14]  P. Morris,et al.  Novel anti-tubulin cytotoxic agents for breast cancer , 2009, Expert review of anticancer therapy.

[15]  G. Navarro,et al.  In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma , 2009, The journal of gene medicine.

[16]  Y. Ouchi,et al.  Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor‐β receptor inhibitor on extravasation of nanoparticles from neovasculature , 2009, Cancer science.

[17]  Steven P Schwendeman,et al.  Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. , 2008, International journal of pharmaceutics.

[18]  Christin Müller,et al.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice , 2008, Journal of Cancer Research and Clinical Oncology.

[19]  J. Siepmann,et al.  PLGA-based drug delivery systems: importance of the type of drug and device geometry. , 2008, International journal of pharmaceutics.

[20]  K. Linnet,et al.  A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs , 2008, European Neuropsychopharmacology.

[21]  Balu Ranganathan,et al.  Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. , 2008, Biomaterials.

[22]  M. Bebawy,et al.  Targeting P-glycoprotein for effective oral anti-cancer chemotherapeutics. , 2008, Current cancer drug targets.

[23]  M. Hussain,et al.  Promising Novel Cytotoxic Agents and Combinations in Metastatic Prostate Cancer , 2008, Cancer journal.

[24]  Shubiao Zhang,et al.  Cationic lipids and polymers mediated vectors for delivery of siRNA. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Sung‐Wook Choi,et al.  Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Donald W. Miller,et al.  Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. , 2007, Molecular pharmaceutics.

[27]  C. Berkland,et al.  Macromolecule release from monodisperse PLG microspheres: control of release rates and investigation of release mechanism. , 2007, Journal of pharmaceutical sciences.

[28]  J. Panyam,et al.  Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. , 2006, International journal of pharmaceutics.

[29]  P. Acott,et al.  BRAIN CYCLOSPORIN A LEVELS ARE DETERMINED BY ONTOGENIC REGULATION OF MDR1A EXPRESSION , 2006, Drug Metabolism and Disposition.

[30]  H. von Briesen,et al.  Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays , 2006, Journal of drug targeting.

[31]  B. Trock,et al.  Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. , 2005, Seminars in oncology.

[32]  D. Piwnica-Worms,et al.  In vivo RNA Interference–Mediated Ablation of MDR1 P-Glycoprotein , 2005, Clinical Cancer Research.

[33]  M. Guan,et al.  Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells. , 2005, Gynecologic Oncology.

[34]  R. Samulski,et al.  Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  You Han Bae,et al.  Super pH-sensitive multifunctional polymeric micelle. , 2005, Nano letters.

[36]  D. Nowotnik,et al.  Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. , 2004, Journal of inorganic biochemistry.

[37]  S. Raguz,et al.  Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1 , 2004, Gene Therapy.

[38]  V. Labhasetwar,et al.  Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. , 2004, Molecular pharmaceutics.

[39]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[40]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[41]  Dong Xu,et al.  Selective Inhibition of P-glycoprotein Expression in Multidrug-Resistant Tumor Cells by a Designed Transcriptional Regulator , 2002, Journal of Pharmacology and Experimental Therapeutics.

[42]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[43]  K. Shakesheff,et al.  Synthesis and Characterisation of a Degradable Poly(lactic acid)−Poly(ethylene glycol) Copolymer with Biotinylated End Groups , 2001 .

[44]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  J. Verweij,et al.  Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  E K Rowinsky,et al.  Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  D. Kerr,et al.  Clinical trials of P-glycoprotein reversal in solid tumours. , 1996, European journal of cancer.

[48]  C. Duhem,et al.  What Does Multidrug Resistance (MDR) Expression Mean in the Clinic? , 1996, The oncologist.

[49]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[50]  S. Ostad,et al.  Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. , 2008, Journal of drug targeting.

[51]  S. Wise.  Nanocarriers as an emerging platform for cancer therapy , 2007 .

[52]  T. M. Chu,et al.  Immunotherapy in a spontaneously developed murine mammary carcinoma with syngeneic monoclonal antibody , 2004, Cancer Immunology, Immunotherapy.

[53]  Brian D. Lee,et al.  Development of a syngeneic in vivo tumor model and its use in evaluating a novel P-glycoprotein modulator, PGP-4008. , 2003, Oncology research.

[54]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[55]  P Couvreur,et al.  Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. , 2000, Biomaterials.

[56]  P. Couvreur,et al.  Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. , 1997, British Journal of Cancer.